Afamelanotide

Afamelanotide is a lab-made compound that helps the skin better handle sunlight. It gently increases skin color, allowing people who are very light-sensitive to spend more time outdoors comfortably. It also supports the skin’s natural protection system against sun damage.

Description

• Afamelanotide, is a synthetic analog of the natural alpha-melanocyte-stimulating hormone (α-MSH).
• Developed to activate the melanocortin-1 receptor (MC1R) to increase melanin production and provide photoprotection.
• Commercially approved under the brand name Scenesse® for the treatment of erythropoietic protoporphyria (EPP).

How It Works

• Binds selectively to MC1R receptors on melanocytes, stimulating eumelanin synthesis and darkening skin pigment.
• Eumelanin absorbs ultraviolet radiation and reduces oxidative stress within skin cells.
• Also exhibits mild anti-inflammatory and antioxidant effects through melanocortin signaling pathways.

Documented Effects

• Clinically shown to increase tolerance to sunlight and reduce phototoxic pain in patients with EPP.
• Produces gradual, even skin pigmentation without UV exposure.
• Demonstrates protection against oxidative and UV-induced DNA damage in skin tissue studies.
• Explored as an adjunct for vitiligo, photoaging, and other pigment disorders.

Theoretical Effects

• Potential applications in sunless tanning and cosmetic photoprotection.
• May reduce inflammation and free radical generation in skin barrier research.
• Synergistic with PT-141 (Bremelanotide) for systemic melanocortin pathway studies, though their targets differ.

Pharmacokinetics

• Half-life: approximately 30–50 minutes after subcutaneous injection.
• Time to peak concentration: around 1–2 hours following administration.
• Steady-state: reached within 2–3 days when delivered by sustained-release implant.

Duration of Effects

• Each implant provides a controlled release lasting about 60 days.
• Skin darkening and light-tolerance improvements can remain noticeable for several weeks after completion.
• Effects fade naturally within 2–3 months once treatment stops.

Reconstitution

• Use bacteriostatic water for reconstitution.
• Example vial: 10 mg Afamelanotide
• Choose reconstitution volume based on dosing convenience:
  • 1 mL water → 10 mg/mL → 1 mg per 10 units
  • 2 mL water → 5 mg/mL → 500 mcg per 10 units
  • 4 mL water → 2.5 mg/mL → 250 mcg per 10 units
• Gently swirl until clear; avoid foaming.
• Refrigerate reconstituted solution (2–8 °C). Use within ~30 days for best stability.

Injectable Dosage Overview (Clinical and Research Reference)

Typical Clinical Dose

• Approved protocol (Scenesse®): one 16 mg subcutaneous (SC) implant every 2 months for EPP patients.
• Provides steady systemic release for approximately 60 days.

Common Research Range

• Typical injectable range: 250–1000 mcg SC daily or every other day for pigmentation or UV-tolerance studies.
• Topical or transdermal formulations have been explored for cosmetic and dermatologic research.

Maximum Dose (Clinical Context)

• Regulated therapeutic exposure equals one 16 mg implant every 60 days.
• Frequent or higher dosing not supported by safety data and may cause excessive pigmentation or nausea.

Standard Cycle Length

• Implant course: continuous 2-month release; can be repeated cyclically under supervision.
• Research protocols: 4–8 weeks of daily or alternate-day injections followed by rest period.

Clinical Notes

• Implant is inserted under the skin of the abdomen by a healthcare provider.
• Injections, when used, should alternate sites to prevent irritation.
• No tapering required; pigment gradually fades after treatment ends.
• Stacking with other melanocortin peptides may enhance effects but increases side-effect likelihood.
• Stable for about 30 days when refrigerated (2–8°C). Protect from light and heat. Avoid freezing.

Safety Notes

• Generally well tolerated in clinical use; most effects are mild—nausea, flushing, or darkening of moles/freckles.
• No hormonal or carcinogenic effects detected in long-term follow-up of approved EPP therapy.
• Ensure purity and authenticity; counterfeit or unregulated peptides vary in potency.
• Approved medically for EPP; other uses remain experimental.